Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
0.8250
+0.0423 (5.40%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Cue Biopharma Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Cue Biopharma stock have an average target of 3.00, with a low estimate of 2.00 and a high estimate of 4.00. The average target predicts an increase of 263.64% from the current stock price of 0.83.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cue Biopharma stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $2 | Buy | Reiterates | $2 | +142.42% | Apr 2, 2025 |
| Stifel | Stifel | Strong Buy Maintains $8 → $4 | Strong Buy | Maintains | $8 → $4 | +384.85% | Aug 20, 2024 |
| JMP Securities | JMP Securities | Buy Maintains $15 → $2 | Buy | Maintains | $15 → $2 | +142.42% | Jul 26, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $8 → $3 | Buy | Maintains | $8 → $3 | +263.64% | Jul 26, 2024 |
| Stifel | Stifel | Strong Buy Maintains $8 | Strong Buy | Maintains | $8 | +869.70% | Apr 9, 2024 |
Financial Forecast
Revenue This Year
5.96M
from 9.29M
Decreased by -35.84%
Revenue Next Year
6.24M
from 5.96M
Increased by 4.77%
EPS This Year
-0.60
from -0.72
EPS Next Year
-0.49
from -0.60
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 12.4M | 13.0M | 13.6M | ||
| Avg | 6.0M | 6.2M | 13.1M | ||
| Low | n/a | n/a | 12.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 33.4% | 117.8% | 118.3% | ||
| Avg | -35.8% | 4.8% | 110.0% | ||
| Low | - | - | 103.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.59 | -0.33 | -0.51 |
| Avg | -0.60 | -0.49 | -0.49 |
| Low | -0.62 | -0.65 | -0.48 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.